Aclaris Therapeutics, Inc.
ACRS
$2.83
-$0.05-1.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.74M | 16.79M | 17.78M | 18.72M | 27.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.74M | 16.79M | 17.78M | 18.72M | 27.08M |
| Cost of Revenue | 47.18M | 47.13M | 44.50M | 43.09M | 55.62M |
| Gross Profit | -31.43M | -30.35M | -26.73M | -24.37M | -28.54M |
| SG&A Expenses | 21.35M | 22.13M | 21.50M | 22.20M | 24.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.55M | 75.22M | 71.96M | 71.25M | 86.14M |
| Operating Income | -65.81M | -58.43M | -54.18M | -52.53M | -59.06M |
| Income Before Tax | -141.68M | -134.65M | -130.21M | -132.07M | -37.37M |
| Income Tax Expenses | -- | -- | -- | -- | -367.00K |
| Earnings from Continuing Operations | -141.68 | -134.65 | -130.21 | -132.07 | -37.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -141.68M | -134.65M | -130.21M | -132.07M | -37.00M |
| EBIT | -65.81M | -58.43M | -54.18M | -52.53M | -59.06M |
| EBITDA | -65.70M | -58.26M | -53.99M | -52.22M | -58.66M |
| EPS Basic | -1.38 | -1.37 | -1.40 | -1.51 | -0.52 |
| Normalized Basic EPS | -0.29 | -0.28 | -0.30 | -0.35 | -0.44 |
| EPS Diluted | -1.38 | -1.37 | -1.40 | -1.51 | -0.52 |
| Normalized Diluted EPS | -0.29 | -0.28 | -0.30 | -0.35 | -0.44 |
| Average Basic Shares Outstanding | 462.90M | 411.66M | 360.37M | 309.05M | 284.61M |
| Average Diluted Shares Outstanding | 462.90M | 411.66M | 360.37M | 309.05M | 284.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |